Our first-in-human clinical study has further indicated that our approach is safe, reliable, and highly effective for treating adolescent and adult patients with B-ALL, paving the road for expanding our F-CAR-T platform to other CAR-T products and conditions other than B-ALL and to antigens beyond CD19. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.